In this context, we have previously shown a downregulation of OCT1 and OCT3 in human HCC and cholangiocellular carcinoma (CCC), associated with tumor progression and a worse patient survival [15, 16]. This evidence concerns the gene SLC22A3 and hepatocellular carcinoma.